Abstract. The purpose of the present study was to identify gene polymorphisms for reliable assessment of genetic factors for type 2 diabetes mellitus. The study population comprised 4853 unrelated Japanese individuals (2688 men, 2165 women), including 1489 subjects with type 2 diabetes mellitus (969 men, 520 women) and 3364 controls (1719 men, 1645 women). The genotypes for 148 polymorphisms of 124 candidate genes were determined with a method that combines polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Sixteen polymorphisms were related (p<0.05) to the prevalence of type 2 diabetes mellitus as determined by the chi-square test. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of smoking revealed that, among these polymorphisms, the -603A→G polymorphism of the gene for coagulation factor III (F3) was significantly (p<0.001) associated with the prevalence of type 2 diabetes mellitus, with the -603G allele representing a risk factor for this condition. A stepwise forward selection procedure demonstrated that F3 genotype (GG versus AA + AG) significantly (p<0.001) and independently affected the prevalence of type 2 diabetes mellitus. Genotype for F3 may prove reliable for assessment of genetic factors for type 2 diabetes mellitus. Determination of the genotype for this gene may contribute to personalized prevention of this condition.
Introduction
Type 2 diabetes mellitus is a multifactorial disease with a substantial genetic component that is thought to be polygenic in nature. A combination of genes thus likely influences the underlying level of glucose intolerance in a population and thereby contributes to the overall susceptibility to type 2 diabetes mellitus. Although genetic linkage analyses (1) (2) (3) (4) (5) and association studies (6-10) have implicated several loci and candidate genes in predisposition to type 2 diabetes mellitus, the genes that contribute to genetic susceptibility to this condition remain to be identified definitively. In addition, given the ethnic differences in lifestyle and environmental factors as well as in genetic background, it is important to examine polymorphisms related to type 2 diabetes mellitus in each ethnic group.
We have now performed a large-scale association study for 148 candidate gene polymorphisms and type 2 diabetes mellitus in 4853 Japanese individuals. The purpose of the present study was to identify gene polymorphisms that confer susceptibility to type 2 diabetes mellitus and thereby to contribute to the personalized prevention of this condition.
Materials and methods
Study population. The study population comprised 4853 unrelated Japanese individuals (2688 men, 2165 women) who either visited outpatient clinics of or were admitted to one of the participating hospitals (Gifu Prefectural Gifu, Tajimi, and Gero Hotspring Hospitals; Hirosaki University Hospital; Reimeikyo Rehabilitation Hospital; and Yokohama General Hospital) between October 2002 and March 2005. The 1489 subjects (969 men, 520 women) with type 2 diabetes mellitus had a fasting plasma glucose concentration of ≥6.93 mmol/l (126 mg/dl) or a blood hemoglobin A 1c (HbA 1c ) of ≥6.5% (or both) or were taking antidiabetes medication. Type 2 diabetes mellitus was defined according to the criteria accepted by the World Health Organization and described previously (11, 12) . Individuals with type 1 diabetes mellitus, with maturity-onset diabetes of the young, with other metabolic or endocrinologic diseases, or with severe liver or renal dysfunction were excluded from the study. Individuals taking drugs that cause secondary diabetes mellitus were also excluded.
The control subjects comprised a total of 3364 individuals (1719 men, 1645 women) who visited the outpatient clinics of participating hospitals for an annual health checkup. They had a fasting plasma glucose concentration of <6.05 mmol/l (110 mg/dl) and a blood HbA 1c of <5.6%, and they had no history of diabetes mellitus or of taking antidiabetes medication. The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University School of Medicine, Hirosaki University School of Medicine, Gifu International Institute of Biotechnology, and participating hospitals, and written informed consent was obtained from each participant.
Selection of polymorphisms.
With the use of public databases, we selected 124 candidate genes that have been characterized and were suggested to be potentially associated with type 2 diabetes mellitus on the basis of a comprehensive overview of the function of pancreatic ß cells, peripheral insulin sensitivity, hepatic glucose production, lipid and adipose tissue metabolism, and other metabolic factors as well as of regulation of blood pressure and endocrine function, vascular biology, monocyte-macrophage biology, lymphocyte and other leukocyte biology, coagulation and fibrinolysis systems, and platelet function. We further selected for analysis 148 polymorphisms of these genes, most of which are located in the promoter region, exons, or splice donor or acceptor sites of introns and might therefore be expected to affect the function or expression of the encoded protein (Supplementary Table I) .
Genotyping of polymorphisms. Venous blood (7 ml) was collected into tubes containing 50 mmol/l EDTA (disodium salt), and genomic DNA was isolated with a kit (Genomix; Talent, Trieste, Italy). Genotypes of the 148 polymorphisms were determined (G&G Science, Fukushima, Japan) by a method that combines polymerase chain reaction and sequencespecific oligonucleotide probes with suspension array technology (Luminex, Austin, TX, USA). Primers, probes, and other conditions for genotyping are shown in Supplementary  Table II . The detailed genotyping methodology was described previously (13) .
Statistical analysis.
Clinical data were compared between subjects with type 2 diabetes mellitus and controls by the unpaired Student's t-test. Qualitative data were compared by the chi-square test. Allele frequencies were estimated by the gene counting method, and the chi-square test was used to identify departures from Hardy-Weinberg equilibrium. The genotype distribution of each autosomal polymorphism was compared between subjects with type 2 diabetes mellitus and controls by the chi-square test (3x2); for polymorphisms on the X chromosome, allele frequencies were compared by the chi-square test (2x2). Polymorphisms related to type 2 diabetes mellitus (p<0.05) were examined by multivariable logistic regression analysis with adjustment for covariates, with type 2 diabetes mellitus as a dependent variable and independent variables including age, sex (0 = woman, 1 = man), smoking status (0 = nonsmoker, 1 = smoker), and genotype of each polymorphism. Each genotype was assessed according to dominant, recessive, and two additive (additive 1 and 2) genetic models, and the p-value, odds ratio, and 95% confidence interval were calculated. Each genetic model comprised two groups: the combined group of variant homozygotes and heterozygotes versus wild-type homozygotes for the dominant model; variant homozygotes versus the combined group of wild-type homozygotes and heterozygotes for the recessive model; heterozygotes versus wild-type homozygotes for the additive 1 model; and variant homozygotes versus wild-type homozygotes for the additive 2 model. We also performed a stepwise forward selection procedure to examine the effects of genotypes as well as of other covariates on type 2 diabetes Table I . Characteristics of the 4853 study subjects. - - Table II . Polymorphisms related (p<0.05) to type 2 diabetes mellitus as determined by the chi-square test.
The levels for inclusion in and exclusion from the model were 0.25 and 0.1, respectively. Given the multiple comparisons of genotypes with type 2 diabetes mellitus, we adopted a strict criterion (p<0.001) for statistical significance of association in order to avoid type I error. For other clinical background data, a p-value of <0.05 was considered statistically significant. Statistical significance was examined by two-sided tests, and statistical analyses were performed with JMP version 5.1 software (SAS Institute, Cary, NC, USA).
Results
The characteristics of the 4853 study subjects are shown in Table I . The frequency of male subjects, body mass index, and the prevalence of smoking, hypertension, and hypercholesterolemia were greater for subjects with type 2 diabetes mellitus than for controls. Comparison of genotype distributions with the chi-square test revealed that 16 polymorphisms were related (p<0.05) to the prevalence of type 2 diabetes mellitus (Table II) . These polymorphisms were further analyzed for their possible association with type 2 diabetes mellitus. Multivariable logistic regression analysis with adjustment for age, sex, and smoking status revealed that the -603A→G polymorphism of the coagulation factor III gene (F3, recessive and additive 2 models) was significantly (p<0.001) associated with the prevalence of type 2 diabetes mellitus, with the -603G allele being a risk factor for this condition (Table III) . The genotype distributions for all 16 polymorphisms related to type 2 diabetes are shown in Table IV ; those in control subjects were in Hardy-Weinberg equilibrium.
Finally, we performed a stepwise forward selection procedure to examine the effects of genotypes for these polymorphisms, age, sex, and smoking status on type 2 diabetes mellitus (Table V) . Sex and F3 genotype (recessive model), in descending order of statistical significance (p<0.001), independently influenced the prevalence of type 2 diabetes mellitus.
Discussion
We have examined the possible relationships of 148 polymorphisms in 124 candidate genes to type 2 diabetes mellitus. Our large-scale association study with 4853 individuals revealed that the -603A→G polymorphism of F3 was significantly associated with the prevalence of type 2 diabetes mellitus in the Japanese population. The chromosomal region containing F3 (1p22-21) has not previously been linked to type 2 diabetes mellitus in the Japanese population (14) (15) (16) , and F3 itself has not been identified as a candidate gene for predisposition to this condition. F3 (tissue factor or tissue thromboplastin) is a 47-kDa transmembrane glycoprotein, which, in response to binding of factor VIIa, activates coagulation factor X by converting it to factor Xa and thereby initiates the extrinsic coagulation cascade. Although F3 is normally not expressed in circulating leukocytes or endothelial cells, transcription of F3 is induced in these cells by proinflammatory cytokines, growth factors, shear forces, or balloon injury of the vessel wall (17) . The abundance of F3 mRNA is increased in several tissues, including adipose tissue, of obese mice compared with those Table III . Multivariable logistic regression analysis of polymorphisms related to type 2 diabetes mellitus. 
Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of smoking. OR, odds ratio; CI, confidence interval. p-values of <0.001 are shown in bold.
-
of lean mice (18, 19) , suggesting that hyperinsulinemia associated with insulin-resistant states, such as obesity and type 2 diabetes mellitus, may induce F3 expression locally in multiple tissues. The expression of F3 was shown to be higher in monocytes from individuals with diabetes mellitus than in those from nondiabetic controls (20) . Although similar numbers of cellderived microparticles were found in both individuals with well-controlled, uncomplicated type 2 diabetes mellitus and nondiabetic controls, a higher proportion of microparticles derived from T helper cells, granulocytes, and platelets exposed F3 in the former group (21) . The plasma concentration of F3 was also higher in individuals with type 2 diabetes mellitus than in nondiabetic controls; furthermore, it was higher in diabetic individuals with cardiovascular disease than in those without this condition, suggesting that F3 levels are related to vascular complications (22, 23) . Indeed, the -603A→G polymorphism of F3 has been associated with myocardial infarction, with the -603G allele being a risk factor for this condition (24) . Moberg et al (25) showed that an instant blood-mediated inflammatory reaction (IBMIR) occurs frequently during transplantation of pancreatic islets. Given that F3 is produced and secreted by the endocrine cells of islets of Langerhans and that the IBMIR is inhibited by antibodies to F3 and site-inactivated factor VIIa in vitro, these researchers concluded that the IBMIR is triggered by Table IV . Genotype distributions of polymorphisms related to type 2 diabetes mellitus. 
-------------------------------------------------Gene Polymorphism Type 2 diabetes Controls symbol mellitus -------------------------------------------------

-------------------------------------------------
F3. These observations suggest that inhibition of F3 activity may be beneficial during clinical islet transplantation. Induction of F3 expression occurs at a transcriptional level through the action of cell type-specific promoters. Transcriptional induction of F3 is mediated by AP-1 and NF-κB sites in endothelial and monocytic cells and by Egr-1 and Sp1 sites in epithelial and smooth muscle cells and monocytes (17) . Various promoter polymorphisms of F3 have been described: four polymorphisms (-1812C→T, -1322C→T, -1208D/I, and -603A→G) are in linkage disequilibrium and two other polymorphisms (-1442G→C and -21C→T) are rare (26) . Individuals homozygous for the D allele of the deletion/ insertion (D/I) polymorphism at nucleotide position -1208 were found to have a lower circulating level of F3 than those homozygous for the I allele (26) . The -603A→G polymorphism was associated with the abundance of F3 mRNA in monocytes, with individuals with the G allele manifesting a larger amount of F3 mRNA than those with the AA genotype (27) . We have now shown that the -603A→G polymorphism of F3 is significantly associated with the prevalence of type 2 diabetes mellitus, with the -603G allele being a risk factor for this condition. This is the first demonstration of an association of a polymorphism of F3 with type 2 diabetes mellitus, although the underlying molecular mechanism remains to be elucidated. Our finding is consistent with previous observations that the levels of F3 in plasma and in various types of cells are increased in diabetic subjects, that increased levels of F3 are deleterious in terms of vascular complications in diabetic individuals and for islet transplantation, and that the G allele of the-603A→G polymorphism is related to increased expression of F3 (20) (21) (22) (23) 25) .
Given the multiple comparisons of genotypes with type 2 diabetes mellitus in the present study, we adopted a strict criterion (p<0.001) for statistical significance of association.
It is not possible, however, to exclude completely potential statistical errors such as false positives. It is also possible that the -603A→G polymorphism of F3 is in linkage disequilibrium with polymorphisms of other nearby genes that are actually responsible for the development of type 2 diabetes mellitus. The functional relevance of the -603A→G polymorphism of F3 to the pathophysiology of type 2 diabetes mellitus was also not examined in the present study. Despite these limitations, our present results suggest that F3 is a susceptibility locus for type 2 diabetes mellitus in the Japanese population. Determination of genotype for this polymorphism may prove informative for assessment of the genetic risk for type 2 diabetes mellitus and may contribute to the personalized prevention of this condition. Table V . Effects of genotypes and other characteristics on type 2 diabetes mellitus as determined by a stepwise forward selection procedure. Supplementary Table I . The 148 polymorphisms examined in the study.
1p34.1-p32 Proprotein convertase, subtilisin/kexin-type, 9 PCSK9 23968A→G (Glu670Gly) rs505151
1p22-p21 Coagulation factor III F3 -603A→G rs1361600
Tumor necrosis factor ligand superfamily, member 4 TNFSF4 A→G rs3850641
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